SPRY4-IT1与乳腺癌

摘要/Abstract

摘要：

长非编码RNA（lncRNA）是一种不编码表达蛋白质的RNA分子，在多种肿瘤的发生、发展中发挥着重要作用。SPRY4-IT1作为一种lncRNA，在乳腺癌组织中高表达，可作为乳腺癌上下游调控因子，促进乳腺癌的进展并与乳腺癌分期及预后密切相关。深入研究SPRY4-IT1与乳腺癌的相关分子机制，可为发现乳腺癌早期诊断生物标志物、评估疾病预后和寻找靶向位点提供新的思路。

关键词:RNA，长链非编码,乳腺肿瘤,SPRY4-IT1

Abstract:

Long non-coding RNA （lncRNA） is an RNA molecule that does not code to express proteins， and plays an important role in the occurrence and development of a variety of tumors. As an lncRNA， SPRY4-IT1 is highly expressed in breast cancer tissues， and can be used as an upstream and downstream regulator of breast cancer， promoting the progression of breast cancer， and is closely related to breast cancer stage and prognosis. In-depth study of the molecular mechanism associated with SPRY4-IT1 and breast cancer can provide new ideas for discovering biomarkers for early diagnosis of breast cancer， assessing disease prognosis and finding targeting sites.

Key words:RNA， long noncoding,Breast neoplasms,SPRY4-IT1

闫学敏, 武霄勇, 张佳谊, 文锦旭, 王跃欣. SPRY4-IT1与乳腺癌[J]. 国际肿瘤学杂志, 2023, 50(10): 627-630.

Yan Xuemin, Wu Xiaoyong, Zhang Jiayi, Wen Jinxu, Wang Yuexin. SPRY4-IT1 and breast cancer[J]. Journal of International Oncology, 2023, 50(10): 627-630.

参考文献32

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660.
[2]	Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040[J].Breast,2022,66: 15-23. DOI:10.1016/j.breast.2022.08.010. pmid:36084384
[3]	朱军, 黄美金, 李媛, 等. HER2低表达乳腺癌的靶向治疗研究进展[J].国际肿瘤学杂志,2023,50(4): 236-240. DOI:10.3760/cma.j.cn371439-20221230-00046.
[4]	Lee J. Current treatment landscape for early triple-negative breast cancer (TNBC)[J].J Clin Med,2023,12(4): 1524. DOI:10.3390/jcm12041524.
[5]	Ren Z, Xue Y, Liu L, et al. Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function[J].Cancer Lett,2023,565: 216221. DOI:10.1016/j.canlet.2023.216221.
[6]	Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches[J].Trends Biochem Sci,2019,44(1): 33-52. DOI:10.1016/j.tibs.2018.09.012. pmid:30459069
[7]	Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA loca-lization and function[J].J Cell Biol,2021,220(2): e202009045. DOI:10.1083/jcb.202009045.
[8]	Abd-Elmawla MA, Hassan M, Elsabagh YA, et al. Deregulation of long noncoding RNAs ANCR, TINCR, HOTTIP and SPRY4-IT1 in plasma of systemic sclerosis patients: SPRY4-IT1 as a novel biomarker of scleroderma and its subtypes[J].Cytokine,2020,133: 155124. DOI:10.1016/j.cyto.2020.155124.
[9]	Fan MJ, Zou YH, He PJ, et al. Long non-coding RNA SPRY4-IT1 promotes epithelial-mesenchymal transition of cervical cancer by regulating the miR-101-3p/ZEB1 axis[J].Biosci Rep,2019,39(6): BSR20181339. DOI:10.1042/BSR20181339.
[10]	Cao S, Lin L, Xia X, et al. lncRNA SPRY4-IT1 regulates cell proliferation and migration by sponging miR-101-3p and regulating AMPK expression in gastric cancer[J].Mol Ther Nucleic Acids,2019,17: 455-464. DOI:10.1016/j.omtn.2019.04.030.
[11]	Ghafouri-Fard S, Khoshbakht T, Taheri M, et al. A review on the role of SPRY4-IT1 in the carcinogenesis[J].Front Oncol,2021,11: 779483. DOI:10.3389/fonc.2021.779483.
[12]	Safa A, Gholipour M, Dinger ME, et al. The critical roles of lncRNAs in the pathogenesis of melanoma[J].Exp Mol Pathol,2020,117: 104558. DOI:10.1016/j.yexmp.2020.104558.
[13]	Ma W, Chen X, Wu X, et al. Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway[J].J Cell Physiol,2020,235(11): 7849-7862. DOI:10.1002/jcp.29438. pmid:31943198
[14]	Li Z, Shen J, Chan MTV, et al. The long non-coding RNA SPRY4-IT1: an emerging player in tumorigenesis and osteosarcoma[J].Cell Prolif,2018,51(4): e12446. DOI:10.1111/cpr.12446.
[15]	Xiang Y, Chen Y, Shi Y, et al. Upregulation of the long non-coding RNA SPRY4-IT1 predicts poor prognosis in breast cancer[J].Int J Clin Exp Pathol,2019,12(3): 1003-1008.
[16]	王焱, 仰大贵, 杨令芝. 乳腺癌组织SPRY4-IT1表达水平及其对患者远期生存的预测价值[J].华中科技大学学报(医学版),2019,48(1): 93-97. DOI:10.3870/j.issn.1672-0741.2019.01.018.
[17]	Mohebi M, Sattari A, Ghafouri-Fard S, et al. Expression profiling revealed up-regulation of three lncRNAs in breast cancer samples[J].Exp Mol Pathol,2020,117: 104544. DOI:10.1016/j.yexmp.2020.104544.
[18]	Zhang Y, Chen H, Yuan R, et al. PDK1-stabilized lncRNA SPRY4-IT1 promotes breast cancer progression via activating NF-κB signaling pathway[J].Mol Carcinog,2023,62(7): 1009-1024. DOI:10.1002/mc.23542.
[19]	Hassine S, Bonnet-Magnaval F, Benoit Bouvrette LP, et al. Staufen1 localizes to the mitotic spindle and controls the localization of RNA populations to the spindle[J].J Cell Sci,2020,133(14): jcs247155. DOI:10.1242/jcs.247155.
[20]	Zhao L, Jiang L, Zhang M, et al. NF-κB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay[J].Oncogene,2021,40(30): 4919-4929. DOI:10.1038/s41388-021-01900-8. pmid:34163032
[21]	Wang HF, Dong ZY, Yan L, et al. The N-terminal polypeptide derived from vMIP-Ⅱ exerts its antitumor activity in human breast cancer through CXCR4/miR-7-5p/Skp2 pathway[J].J Cell Physiol,2020,235(12): 9474-9486. DOI:10.1002/jcp.29755.
[22]	Yang QL, Zhang LY, Wang HF, et al. The N-terminal polypeptide derived from viral macrophage inflammatory protein Ⅱ reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism[J].Oncotarget,2017,8(23): 37448-37463. DOI:10.18632/oncotarget.16394.
[23]	Wu H, Wang Y, Chen T, et al. The N-terminal polypeptide derived from vMIP-Ⅱ exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1[J].Biosci Rep,2018,38(5): BSR20180411. DOI:10.1042/BSR20180411.
[24]	Shi Y, Li J, Liu Y, et al. The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression[J].Mol Cancer,2015,14: 51. DOI:10.1186/s12943-015-0318-0. pmid:25742952
[25]	Zhang X, Mu X, Huang O, et al. ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis[J].BMC Cancer,2022,22(1): 226. DOI:10.1186/s12885-022-09286-w. pmid:35236318
[26]	Song X, Zhang X, Wang X, et al. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2[J].J Cell Mol Med,2020,24(1): 772-784. DOI:10.1111/jcmm.14786. pmid:31736268
[27]	Zheng A, Zhang L, Song X, et al. Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy[J].Histol Histopathol,2020,35(4): 361-370. DOI:10.14670/HH-18-175. pmid:31638266
[28]	El-Helkan B, Emam M, Mohanad M, et al. Long non-coding RNAs as novel prognostic biomarkers for breast cancer in Egyptian women[J].Sci Rep,2022,12(1): 19498. DOI:10.1038/s41598-022-23938-8. pmid:36376369
[29]	Qin X, Yin Q, Gao J, et al. Prognostic role of SPRY4-IT1 in female breast carcinoma and malignant tumors of the reproductive system: a meta-analysis[J].Medicine (Baltimore),2022,101(16): e28969. DOI:10.1097/MD.0000000000028969.
[30]	Wang HM, Li HJ, Chen JZ, et al. Prognostic value of long nonco-ding RNA SPRY4-IT1 on survival outcomes in human carcinomas: a systematic review and meta-analysis with TCGA database[J].Biomed Res Int,2020,2020: 5868602. DOI:10.1155/2020/5868602.
[31]	Pourramezan Z, Attar FA, Yusefpour M, et al. Circulating lncRNAs landscape as potential biomarkers in breast cancer[J].Cancer Rep (Hoboken),2023,6(2): e1722. DOI:10.1002/cnr2.1722.
[32]	Wasson MD, Brown JM, Venkatesh J, et al. Datasets exploring putative lncRNA-miRNA-mRNA axes in breast cancer cell lines[J].Data Brief,2021,37: 107241. DOI:10.1016/j.dib.2021.107241.

SPRY4-IT1 and breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献32

相关文章15

编辑推荐

Metrics

本文评价

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	柳洋, 蒋路路, 管凯文, 周岳阳, 康小红.linc01410在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(9): 540-543.
[9]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[10]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[11]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[12]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳.沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[13]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[14]	周婷, 徐少华, 梅林.贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[15]	拜莹, 李琦, 李亚芹, 赵卫红.E2F1与lncRNA在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 164-168.